These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1562 related articles for article (PubMed ID: 32519113)

  • 1. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
    Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
    Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
    Cowie MR; Lamy A; Levy P; Mealing S; Millier A; Mernagh P; Cristeau O; Bowrin K; Briere JB
    Cardiovasc Res; 2020 Sep; 116(11):1918-1924. PubMed ID: 31807773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
    Zomer E; Si S; Hird TR; Liew D; Owen AJ; Tonkin A; Reid CM; Ademi Z
    Eur J Prev Cardiol; 2019 May; 26(8):858-868. PubMed ID: 30526023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands.
    Spoorendonk JA; Briere JB; Bowrin K; Millier A; Coppens M; Tempelaar S; Verheggen B
    J Med Econ; 2021; 24(1):1231-1239. PubMed ID: 34749569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective.
    Lamy A; Eikelboom J; Tong W; Yuan F; Bangdiwala SI; Bosch J; Connolly S; Lonn E; Dagenais GR; Branch KRH; Wang WJ; Bhatt DL; Probstfield J; Ertl G; Störk S; Steg PG; Aboyans V; Durand-Zaleski I; Ryden L; Yusuf S;
    Am J Cardiovasc Drugs; 2024 Jan; 24(1):117-127. PubMed ID: 38153624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of ankle-brachial index screening in patients with coronary artery disease to optimize medical management.
    Minami HR; Itoga NK; George EL; Garcia-Toca M
    J Vasc Surg; 2021 Dec; 74(6):2030-2039.e2. PubMed ID: 34175383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy.
    Ferrara P; Cortesi PA; Di Laura D; Maggioni AP; Mantovani LG
    Clin Drug Investig; 2021 May; 41(5):459-468. PubMed ID: 33725323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases.
    Lee MC; Liao CT; Toh HS; Chou CC; Chang WT; Chen ZC; Wu WS; Yu T; Strong C
    Cardiovasc Drugs Ther; 2021 Jun; 35(3):539-547. PubMed ID: 32910340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial.
    Lamy A; Eikelboom J; Tong W; Yuan F; Bangdiwala SI; Bosch J; Connolly S; Lonn E; Dagenais GR; Branch KRH; Wang WJ; Bhatt DL; Probstfield J; Ertl G; Störk S; Steg PG; Aboyans V; Durand-Zaleski I; Ryden L; Yusuf S
    Eur Heart J Qual Care Clin Outcomes; 2023 Aug; 9(5):502-510. PubMed ID: 36001989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of screening for peripheral artery disease in patients with coronary artery disease in China: A Markov model.
    Xing Y; Qiu Y; Yang L; Yuan Z; Wang Y
    Int J Cardiol; 2023 Jan; 371():420-426. PubMed ID: 36228765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
    Coppens M; Weitz JI; Eikelboom JWA
    Circ Res; 2019 Feb; 124(3):416-425. PubMed ID: 30702997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective.
    Ademi Z; Zomer E; Tonkin A; Liew D
    Int J Cardiol; 2018 Nov; 270():54-59. PubMed ID: 30220379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials.
    Bauersachs R; Wu O; Briere JB; Bowrin K; Borkowska K; Jakubowska A; Taieb V; Toumi M; Huelsebeck M
    Cardiovasc Ther; 2020; 2020():3057168. PubMed ID: 32695228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation.
    Jacobs MS; de Jong LA; Postma MJ; Tieleman RG; van Hulst M
    Eur J Health Econ; 2018 Sep; 19(7):957-965. PubMed ID: 29181817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of antithrombotic agents for atrial fibrillation in older adults at risk for falls: a mathematical modelling study.
    Wong EKC; Belza C; Naimark DMJ; Straus SE; Wijeysundera HC
    CMAJ Open; 2020; 8(4):E706-E714. PubMed ID: 33158928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pandor A; Pollard D; Chico T; Henderson R; Stevenson M
    Pharmacoeconomics; 2016 May; 34(5):463-77. PubMed ID: 26689783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China.
    Dong SJ; Wu B; Zhai SD; Zhang YJ; Chu YB; Gupta P; Li YH
    Clin Ther; 2020 Jan; 42(1):144-156.e1. PubMed ID: 31932080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
    Darmon A; Elbez Y; Bhatt DL; Abtan J; Mas JL; Cacoub P; Montalescot G; Billaut-Laden I; Ducrocq G; Steg PG
    Ann Cardiol Angeiol (Paris); 2020 Oct; 69(4):158-166. PubMed ID: 32778388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK.
    Folkerts K; Broughton J; Sheikh U; Mckaig S
    J Med Econ; 2019 Nov; 22(11):1179-1191. PubMed ID: 31433687
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function.
    Salcedo J; Hay JW; Lam J
    Int J Cardiol; 2019 May; 282():53-58. PubMed ID: 30518479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.